

Raffaele Di Francia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6659146/publications.pdf>

Version: 2024-02-01

50
papers

1,156
citations

411340

20
h-index

466096

32
g-index

51
all docs

51
docs citations

51
times ranked

2062
citing authors

#	ARTICLE	IF	CITATIONS
1	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. <i>Antioxidants</i> , 2022, 11, 1090.	2.2	12
2	Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. <i>Cancers</i> , 2021, 13, 966.	1.7	46
3	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. <i>Antioxidants</i> , 2020, 9, 1182.	2.2	49
4	Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 643-655.	0.6	2
5	Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study. <i>Frontiers in Oncology</i> , 2020, 10, 594.	1.3	39
6	Resveratrol in Cancer Patients: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2945.	1.8	57
7	Current predictive pathology in the clinical setting of colorectal cancer. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 481-482.	0.5	0
8	Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. <i>Medicina (Lithuania)</i> , 2019, 55, 414.	0.8	18
9	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 443.	1.3	25
10	Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors. <i>Cells</i> , 2019, 8, 522.	1.8	8
11	Pharmacogenomics as a tool to prevent drug-related hospitalization of elderly cardiology-oncology patients receiving chemotherapeutic agents and multiple symptomatic treatments: a pilot study planned for the Italian health system. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 8695-8701.	0.5	1
12	High incidence of MTHFR, CBS, and MTRR polymorphisms in vitiligo patients. Preliminary report in a retrospective study. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 471-478.	0.5	4
13	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. <i>Current Cancer Drug Targets</i> , 2018, 18, 430-441.	0.8	1
14	Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy. <i>Current Cancer Drug Targets</i> , 2018, 18, 499-511.	0.8	48
15	Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies. <i>Oncotarget</i> , 2018, 9, 20807-20815.	0.8	13
16	Sonoporation by microbubbles as gene therapy approach against liver cancer. <i>Oncotarget</i> , 2018, 9, 32182-32190.	0.8	22
17	Serum and tissue markers in colorectal cancer: State of art. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 103-116.	2.0	20
18	Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results. <i>Frontiers in Pharmacology</i> , 2017, 8, 797.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. <i>Oncotarget</i> , 2017, 8, 24401-24414.	0.8	99
20	Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2016, 7, 428.	1.6	63
21	Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antitumor Chemotherapy in Cancer Patients with HIV Infection. <i>Frontiers in Pharmacology</i> , 2016, 7, 71.	1.6	31
22	Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. <i>Frontiers in Pharmacology</i> , 2016, 7, 387.	1.6	19
23	New treatment strategies for HIV-positive cancer patients undergoing antitumor chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2391-2403.	0.9	7
24	Endocrine disruptors and female cancer: Informing the patients (Review). <i>Oncology Reports</i> , 2015, 34, 3-11.	1.2	22
25	The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 123-138.	0.7	18
26	Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 2521-2.	0.5	2
27	Clinical presentation and outcome of non-AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors activity. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 3619-34.	0.5	14
28	Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 4443-54.	0.5	8
29	Norethisterone acetate/estradiol hormonal oral contraceptive and breast cancer risk. <i>Anti-Cancer Drugs</i> , 2014, 25, 745-750.	0.7	7
30	Current strategies to minimize toxicity of oxaliplatin. <i>Anti-Cancer Drugs</i> , 2013, 24, 1069-1078.	0.7	29
31	Promestriene, a specific topical estrogen. Review of 40 years of vaginal atrophy treatment. <i>Anti-Cancer Drugs</i> , 2013, 24, 989-998.	0.7	24
32	Nutrition in oncologic patients during antitumor treatment. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 120.	3.0	2
33	Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1332-1343.	0.9	14
34	Antitumor Treatment, for Solid Tumors, during Pregnancy: A Crucial Decision. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 1-19.	1.0	1
35	Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them. <i>European Review for Medical and Pharmacological Sciences</i> , 2012, 16, 285-98.	0.5	2
36	Knowledge and skills needs for health professions about pharmacogenomics testing field. <i>European Review for Medical and Pharmacological Sciences</i> , 2012, 16, 781-8.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1105-1111.	1.4	15
38	Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 447-59.	1.4	15
39	Functional coexpression of Interleukin (IL)â€7 and its receptor (ILâ€7R) on Hodgkin and Reedâ€Sternberg cells: Involvement of ILâ€7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2009, 125, 1092-1101.	2.3	103
40	Elevation of clonal serum free light chains in patients with HIVâ€negative primary effusion lymphoma (PEL) and PELâ€like lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 405-408.	1.2	13
41	Expression of the Brain Transcription Factor OTX1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive Non-Hodgkin Lymphoma. <i>American Journal of Pathology</i> , 2009, 175, 2609-2617.	1.9	25
42	Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosomeâ€positive leukemia. <i>Blood</i> , 2009, 113, 5028-5029.	0.6	14
43	Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 723-730.	0.6	11
44	Rapid Reversion of Loeffler's Endocarditis by Imatinib in Early Stage Clonal Hypereosinophilic Syndrome. <i>Leukemia and Lymphoma</i> , 2004, 45, 2503-2507.	0.6	47
45	Hyaluronanâ€CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. <i>Journal of Cell Biology</i> , 2002, 158, 1133-1144.	2.3	83
46	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002, 117, 59-69.	1.2	10
47	Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. <i>British Journal of Haematology</i> , 2002, 118, 1055-1064.	1.2	22
48	A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. <i>Journal of Pathology</i> , 2002, 197, 256-263.	2.1	13
49	CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001, 508, 418-422.	1.3	20
50	Normalizing Complementary DNA by Quantitative Reverse Transcriptaseâ€Polymerase Chain Reaction of Î²2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 98-109.	2.1	19